You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

 

Online download statistics by month:

Online download statistics by month: October 2020 to March 2026

AbstractFullPdf
Oct 202012671267511
Nov 2020270270132
Dec 202013013058
Jan 202120420468
Feb 2021388388112
Mar 202121321394
Apr 202117917965
May 202114914970
Jun 202118318271
Jul 202110510544
Aug 202113813861
Sep 202113613652
Oct 202114814872
Nov 202114714769
Dec 202112012239
Jan 202210911763
Feb 2022586235
Mar 202211712650
Apr 202225525951
May 202211612052
Jun 202210811527
Jul 202212712838
Aug 202211812059
Sep 2022858694
Oct 202210010551
Nov 202211311349
Dec 2022727234
Jan 2023747528
Feb 2023979944
Mar 2023969930
Apr 2023454726
May 2023545625
Jun 2023646720
Jul 2023848435
Aug 2023606132
Sep 2023545522
Oct 2023808019
Nov 202311311424
Dec 2023727222
Jan 2024606144
Feb 2024828239
Mar 2024606138
Apr 2024777842
May 2024646325
Jun 2024636237
Jul 2024495321
Aug 2024616025
Sep 2024363618
Oct 2024676845
Nov 2024676939
Dec 202410010148
Jan 202510410457
Feb 202510210238
Mar 2025868749
Apr 202511011039
May 202511511859
Jun 202517017224
Jul 2025110
Sep 2025110
Dec 2025100
Mar 2026110
Total752576003135